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Abstract. Colon cancer accounts for a large proportion of all 
the cancer -associated morbidities worldwide. Genetic analysis 
and stratification of patients based on survival may identify 
genetic signatures potentially useful for prognostic or treatment 
planning purposes. Previous studies have reported that the 
messenger (m)RNA expression levels of tafazzin (TAZ), AXL 
receptor tyrosine kinase (AXL) and connective tissue growth 
factor (CTGF) were able to predict the survival of patients 
with colon cancer in two independent colon cancer datasets. 
However, limited clinicopathological data were available from 
these two datasets. By contrast, a large colon cancer dataset 
comprising 566 patients has been recently published in the Gene 
Expression Omnibus database, which contains data regarding 
tumor stage and location, and genetic status of mismatch 
repair (MMR), Kirsten rat sarcoma viral oncogene homolog 
(KRAS), B-Raf proto-oncogene serine/threonine kinase 
(BRAF) and tumor protein p53 (TP53). In the present study, 
the mRNA expression levels of TAZ, AXL and CTGF were 
evaluated, and the TAZ-AXL-CTGF signature was correlated 
with the available pathological parameters and survival data. 
Overexpression of TAZ, AXL and CTGF was observed to be 
associated with severe pathological stage, deficiency in MMR, 
colon cancer subtype C4 and mutations in the BRAF gene. In 
addition, overexpression of TAZ‑AXL‑CTGF was associated 
with short overall survival in patients with mutations in the 
TP53 gene, colon cancer subtype C6, proficient MMR and 
wild-type status of the KRAS and BRAF genes. Furthermore, 
the prognostic value of TAZ‑AXL‑CTGF overexpression 
was observed to be independent of all the clinicopathological 
parameters and mutational statuses analyzed. The results of 
the present study confirm the previously reported findings, 
and suggest that the TAZ-AXL-CTGF mRNA signature is a 
potential prognostic indicator in colon cancer.
Introduction
The morbidity rates exhibited by patients with colon cancer 
are among the highest of all types of cancer. Therefore, the 
identification of novel prognostic markers for colon cancer is 
important for appropriate treatment planning, in order to ensure 
that patients receive more efficacious and less toxic treatment 
regimens (1). Recent advances in colon cancer research have 
led to the identification of Kirsten rat sarcoma viral oncogene 
homolog (KRAS) and neuroblastoma RAS viral oncogene 
homolog as negative predictive markers, and to the introduc-
tion of novel treatment agents, including bevacizumab and 
anti‑epidermal growth factor receptor (EGFR)s, which have 
resulted in median overall survival >30 months in patients 
with metastatic colorectal cancer (2). Despite these advances, 
no positive predictors for response and treatment outcome in 
these patients have been identified thus far. For early colon 
cancer, microsatellite instability is a well-known prognostic 
factor. However, the identification of further prognostic 
markers has experienced limited success in recent years (3). 
Tafazzin (TAZ), also known as WW domain containing tran-
scription regulator 1 (WWTR1), is an important transcription 
coactivator and a key downstream effector of the mammalian 
Hippo signaling pathway (4), which participates in the devel-
opment of colon cancer (5,6).
The use of the messenger (m)RNA expression levels of 
TAZ and its downstream factors AXL receptor tyrosine 
kinase (AXL) and connective tissue growth factor (CTGF) 
as a three-gene signature for the prognosis of patients with 
colon cancer has been previously reported in two indepen-
dent cohort datasets (5). However, these datasets did not 
contain clinicopathological data of the patients, contrarily 
to the cohort Gene Expression Omnibus Series (GSE)40967, 
which has been recently submitted to the Gene Expres-
sion Omnibus (GEO) database (http://www.ncbi.nlm.nih.
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gov/geo/) (7). At present, no other GEO database regarding 
colon cancer cohorts contains more patients for whom gene 
expression and patient relapse‑free survival outcome data are 
available than the aforementioned GSE40967 cohort, which 
describes a number of clinicopathological parameters of 
566 patients with colon cancer, including age, gender, tumor 
stage and location (distal or proximal), survival outcome 
and response to adjuvant chemotherapy. This dataset also 
details genetic parameters of the patients, including status 
of mismatch repair (MMR) and mutational status of KRAS, 
B-Raf proto-oncogene serine/threonine kinase (BRAF) and 
tumor protein p53 (TP53) genes. Due to this combination 
of genetic and clinicopathological data, GSE40967 may be 
a powerful tool for confirming the prognostic potential of 
the TAZ-AXL-CTGF mRNA expression signature in colon 
Table I. Clinicopathological features of the patients in the 
dataset GSE40967.
Characteristics No. of cases %
Age, years 566 
  Median (range)  68 (22-97)
Gender
  Female 256 45.2
  Male 310 54.8
Tumor stage
  0     4   0.71
  1   33   5.83
  2 264 46.64
  3 205 36.22
  4   60 10.60
Tumor location
  Proximal 224 39.6
  Distal 342 60.4
Colon cancer subtype
  C1 116 20.495
  C2 104 18.375
  C3   75 13.251
  C4   59 10.424
  C5 152 26.855
  C6    60 10.600
MMR status
  Proficient 444 78.4
  Deficient   75 13.3
  Missing   47   8.3
BRAF status
  Wild-type 461 81.4
  Mutant   51   9.0
  Missing   54   9.5
KRAS status
  Wild-type 328 58.0
  Mutant 217 38.3
  Missing   21   3.7
TP53 status
  Wild-type 161 28.4 
  Mutant 190 33.6
  Missing 215 38.0
GSE, Gene Expression Omnibus Series; C1, chromosome 
instability-immune down; C2, deficient MMR subtype; C3, 
KRAS mutant subtype; C4, cancer stem cell subtype; C5, chro-
mosome instability-int/Wingless-up subtype; C6, chromosome 
instability-normal-like subtype; MMR, mismatch repair; BRAF, 
B-Raf proto-oncogene serine/threonine kinase; KRAS, Kirsten rat 
sarcoma viral oncogene homolog.
  
Figure 1. Correlation between survival and the expression levels of TAZ, 
AXL and CTGF in the dataset GSE40967. Correlation between the mRNA 
expression levels of TAZ and the mRNA expression levels of (A) AXL 
and (B) CTGF in patients with colon cancer. (C) Association between the 
TAZ‑AXL‑CTGF expression signature and relapse‑free survival in patients 
with colon cancer. TAZ, tafazzin; CTGF, connective tissue growth factor; 
mRNA, messenger RNA; GSE, Gene Expression Omnibus Series.
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cancer. In addition, the comprehensive information provided by 
GSE40967 may enable to determine the association between 
the aforementioned genetic and clinicopathological character-
istics and the prognostic significance of the TAZ‑AXL‑CTGF 
signature in patients with colon cancer, which was not possible 
to test in the previous study by Yuen et al (5).
Materials and methods
Microarray gene expression data were retrieved from the data 
matrixes deposited in the GEO database by Marisa et al (7). 
R scripting was used to extract the expression values from 
the probe sets for TAZ, AXL and CTGF, and the clinical 
data from the data matrixes available at GEO, as previously 
described (5). All statistical analyses were performed using 
SPSS software, version 19.0 (IBM SPSS, Armonk, NY, 
USA). The association between the expression levels of TAZ, 
AXL and CTGF were analyzed by Spearman's rank test. The 
mRNA expression levels of these genes were classified as high 
or low, using the value of the median expression level as the 
cut‑off point. Patients were divided into three groups, based 
on the expression levels of TAZ, AXL and CTGF, as follows: 
i) The TAZ-AXL-CTGF-low group consisted of patients 
who exhibited low expression levels (below the median 
value) of these three genes; ii) the TAZ‑AXL‑CTGF‑high 
group consisted of patients who displayed high expression 
levels (above the median value) of these three genes; and 
iii) the TAZ-AXL-CTGF-intermediate group consisted of 
patients who presented other expression patterns of the above 
three genes. The survival time of patients stratified by this 
grouping method were analyzed by Kaplan-Meier and Cox 
regression analyses. Multivariate Cox regression analysis 
was performed including all the available clinicopathological 
parameters, genetic statuses and mRNA expression levels of 
TAZ, AXL and CTGF, using a forward conditional stepwise 
regression method with an entry criteria of P<0.05, which was 
considered to indicate a statistically significant difference. The 
clinicopathological data of the patients are detailed in Table I. 
The sample size was different for each analysis due to varia-
tions in the data available for each patient.
Results and Discussion
As represented in Fig. 1, a significantly positive correlation 
was observed between the mRNA expression levels of TAZ 
and the mRNA expression levels of AXL (Spearman's rank 
test, r=0.681, P<0.001, n=566; Fig. 1A) and CTGF (Spearman's 
rank test, r=0.644, P<0.001, n=566; Fig. 1B). These findings 
  B  A
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Figure 2. Association between the TAZ-AXL-CTGF expression signature and clinicopathological parameters in patients with colon cancer. Histogram dis-
playing the different TAZ‑AXL‑CTGF expression signatures observed in patients stratified based on their (A) tumor stage, (B) MMR status, (C) tumor subtype 
classification and (D) BRAF mutational status. TAZ, tafazzin; CTGF, connective tissue growth factor; MMR, mismatch repair; BRAF, B-Raf proto-oncogene, 
serine/threonine kinase.
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Figure 3. Kaplan‑Meier survival curves representing the association between the expression levels of TAZ‑AXL‑CTGF and survival in patients with (A) pro-
ficient MMR, (B) deficient MMR, (C) wild‑type KRAS/BRAF, (D) mutant KRAS/BRAF, (E) wild‑type TP53 and (F) mutant TP53. TAZ, tafazzin; CTGF, 
connective tissue growth factor; MMR, mismatch repair; KRAS, Kirsten rat sarcoma viral oncogene homolog; BRAF, B-Raf proto-oncogene serine/threonine 
kinase; TP53, tumor protein p53.
Figure 4. Kaplan‑Meier survival curves representing the association between the expression levels of TAZ‑AXL‑CTGF and survival in patients with subtype 
(A) C6 and (B) C4 tumors. TAZ, tafazzin; CTGF, connective tissue growth factor.
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are consistent with the fact that TAZ is a transcriptional 
regulator for AXL and CTGF (5). In addition, high expres-
sion levels of TAZ‑AXL‑CTGF (n=176) were associated with 
shorter relapse‑free survival, compared with intermediate 
and low expression levels of these three genes (log‑rank test, 
P= 0.040 and 0.014, n=214 and 163, respectively; Fig. 1C). 
Table II. Cox regression analysis of survival of patients with colon cancer.
 Univariate analysis Multivariate analysis
Clinicopathological --------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
variables Hazard ratio (95% CI) P‑value Hazard ratio (95% CI) P‑value
Age (n=552) 1.000 (0.989-1.011) 0.945
Gender
  Female (n=249) 1 Reference
  Male (n=304) 1.271 (0.941-1.717) 0.115
Tumor stage
  I (n=32) 1 Reference 1 Reference
  II (n=260) 7.717 (1.069-55.701)   0.043 5.232 (0.717-38.209) 0.103
  III (n=201) 14.809 (2.061-106.430)   0.007 6.649 (0.911-48.541) 0.062
  IV (n=60) 52.845 (7.232-386.123) <0.001 29.934 (3.894-230.075) 0.001
Adjuvant chemotherapy
  No (n=305) 1 Reference
  Yes (n=232) 1.791 (1.313-2.443) <0.001
Tumor location
  Proximal (n=216) 1 Reference
  Distal (n=337) 1.285 (0.941-1.754) 0.115
MMR status
  Proficient (n=436) 1 Reference 1 Reference
  Deficient (n=71) 0.361 (0.190‑0.684) 0.002 0.404 (0.176‑0.930) 0.033
KRAS status
  Wild-type (n=322) 1 Reference
  Mutant (n=210) 1.436 (1.061-1.943) 0.019
BRAF status
  Wild-type (n=450) 1 Reference
  Mutant (n=49) 0.928 (0.525-1.639) 0.504
TP53 status
  Wild-type (n=155) 1 Reference
  Mutant (n=188) 1.353 (0.952-1.925) 0.136
TAZ-AXL-CTGF status
  Low (n=163) 1 Reference 1 Reference
  Intermediate (n=214) 1.138 (0.775-1.670) 0.511 1.609 (0.927-2.792) 0.091
  High (n=176) 1.609 (1.098-2.357) 0.015 2.646 (1.513-4.627) 0.001
Colon cancer subtype
  C1 (n=114) 1 Reference
  C2 (n=101) 0.524 (0.302-0.912) 0.022
  C3 (n=67) 0.844 (0.485-1.467) 0.547
  C4 (n=59) 1.920 (1.180-3.124) 0.009
  C5 (n=152) 0.922 (0.599-1.418) 0.712
  C6 (n=60) 1.394 (0.844-2.302) 0.195
Survival data was available for 553 patients. The patient numbers do not equal 553 in each univariate analysis due to variation in the availability 
of data. Missing data was not included in the Cox‑regression analysis. CI, confidence interval; MMR, mismatch repair; KRAS, Kirsten rat 
sarcoma viral oncogene homolog; BRAF, B-Raf proto-oncogene, serine/threonine kinase; TP53, tumor protein p53; TAZ, tafazzin; CTGF, 
connective tissue growth factor; C1, chromosome instability-immune down; C2, dMMR subtype; C3, KRAS mutant subtype; C4, cancer stem 
cell subtype; C5, chromosome instability-int/Wingless-up subtype; C6, chromosome instability-normal-like subtype.
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These results are in agreement with the results previously 
obtained using two colon cancer datasets (5). Similarly to 
the previous report by Yuen et al (5), the expression levels 
of TAZ-AXL-CTGF were positively correlated with tumor 
stage (χ2 test, P=0.017, n=562; Fig. 2A). High expression 
levels of TAZ‑AXL‑CTGF were also associated with defi-
ciency in MMR (χ2 test, P<0.001, n=515; Fig. 2B), colon 
cancer subtype C4 (χ2 test, P<0.001, n=562; Fig. 2C), and 
mutant BRAF status (χ2 test, P=0.004, n=508; Fig. 2D). 
The TAZ-AXL-CTGF-high and -low groups were further 
compared, and differential expression of the MMR-signa-
ture‑associated genes was identified (8). Thus, the expression 
levels of genes that are usually overexpressed in MMR‑profi-
cient colon cancer, including reduced nicotinamide adenine 
dinucleotide phosphate oxidase 1, quinolinate phosphoribo-
syltransferase, 3-hydroxy-3-methylglutaryl-CoA synthase 2, 
arylsulfatase E, γ-glutamyl hydrolase, glutathione 
peroxidase 2, serine peptidase inhibitor Kazal type 1, 
transcription factor 7, inhibitor of DNA binding 1, B-cell 
chronic lymphocytic leukemia/lymphoma 11A, indian 
hedgehog, guanylate cyclase 2C, protein kinase adenosine 
monophosphate‑activated β 1, Achaete-Scute complex 
homolog 2, pleiomorphic adenoma gene-like 2, transcription 
factor-like 5, kinesin family member 3B, villin 1, cadherin, 
EGF laminin A seven‑pass G‑type receptor 3, gap junction 
protein β 1, solute carrier family 5 (sodium/glucose cotrans-
porter) member 1, dipeptidase 1, transmembrane 9 superfamily 
protein member 4 and family with sequence similarity 3 
member A, were reduced in the TAZ-AXL-CTGF-high 
group, compared with the TAZ-AXL-CTGF-low group. 
By contrast, genes that are normally overexpressed in 
MMR-deficient colon cancer, including dual specificity 
phosphatase 4, cysteine-rich protein 1, major histocompat-
ibility complex class I polypeptide-related sequence B, 
granzyme A, matrix metalloproteinase-12, secreted phospho-
protein 1, v‑set and immunoglobulin domain containing 4, 
uridine phosphorylase 1 and tribbles pseudokinase 2, were 
significantly overexpressed in the TAZ‑AXL‑CTGF‑high 
group, compared with the TAZ-AXL-CTGF-low group. 
These results indicate that the aforementioned genes may be 
involved in the association between the TAZ‑AXL‑CTGF 
signature and the MMR status displayed by patients with 
colon cancer (data not shown).
A significant association was observed between 
high expression levels of TAZ‑AXL‑CTGF and poor 
relapse-free survival in patients with MMR‑proficient colon 
cancer (log-rank test, P=0.002; Fig. 3A), but not in those 
with deficient MMR status (log‑rank test, P=0.905; Fig. 3B). 
Similarly, this TAZ-AXL-CTGF signature was associated 
with poor relapse‑free survival in patients with wild‑type 
KRAS/BRAF (log‑rank test, P=0.033; Fig. 3C) but not in those 
with mutant KRAS/BRAF (log‑rank test, P=0.312; Fig. 3D). 
Furthermore, the expression levels of TAZ‑AXL‑CTGF were 
associated with poor relapse‑free survival in patients with 
mutant TP53 (log‑rank test, P=0.002; Fig. 3E), contrarily to 
those with wild‑type TP53 (log‑rank test, P=0.153; Fig. 3F).
A previous study classified colon cancer into six  different 
subtypes, of which, C4 and C6 subtypes were observed 
to be associated with poor prognosis (7). In the present 
study, the expression levels of TAZ, AXL and CTGF were 
significantly associated with poor prognosis in patients with 
colon cancer subtype C6 (log‑rank test, P=0.003; Fig. 4A), 
but no significant association was observed for subtype C4 
(log‑rank test, P=0.644; Fig. 4B). All the available clinico-
pathological parameters, in addition to data regarding the 
genetic status and expression levels of TAZ, AXL and 
CTGF, were subsequently included in a multivariate Cox 
regression analysis, which demonstrated that tumor stage 
[stage II, hazard ratio (HR) = 5.232, 95% confidence interval 
(CI) = 0.717‑38.209, P=0.103; stage III, HR = 6.649, 95% 
CI = 0.911-48.541, P=0.062; and stage IV, HR = 29.934, 95% 
CI = 3.894‑230.075, P=0.001], expression levels of TAZ, 
AXL and CTGF (intermediate levels, HR = 1.609, 95%, 
CI = 0.927‑2.792, P=0.091; and high levels, HR = 2.646, 
95% CI = 1.513‑4.627, P=0.001) and deficient MMR status 
(HR = 0.404, 95% CI = 0.176‑0.930, P=0.033; Table II) were 
independent predictors for relapse-free survival in the patient 
cohort analyzed in the present study.
According to previous studies, tumor stage appears to 
be the strongest predictor for poor survival in patients with 
colon cancer (9), while mutations in the BRAF gene have 
also been demonstrated to be associated with poor prognosis 
in colon cancer (10,11). The results of the present study 
indicated that high expression levels of TAZ, AXL and 
CTGF were associated with these two prognostic factors. 
However, the prognostic significance of TAZ‑AXL‑CTGF 
was solely detected in patients with wild-type BRAF and 
KRAS tumors. Overexpression of TAZ, AXL and CTGF 
was also observed to be associated with poor prognosis in 
patients with C4 colon cancer subtype (7), indicating that the 
increased aggressive behavior of this subtype of colon cancer 
may be TAZ-AXL-CTGF-dependent. Furthermore, the 
expression signature of TAZ-AXL-CTGF was able to predict 
the survival of patients with C6 subtype tumors, who also 
exhibited poor prognosis. Therefore, TAZ, AXL and CTGF 
appear to participate in the development of C4 and C6, the 
two most aggressive subtypes of colon cancer.
In addition, the expression of TAZ, AXL and CTGF was 
associated with deficiency in MMR, which is a favorable 
prognostic marker (12,13). However, the relevance of this asso-
ciation remains unknown. Nonetheless, the mRNA expression 
levels of TAZ‑AXL‑CTGF were observed to be associated 
with survival in patients with MMR‑proficient tumors, but 
not in those with MMR‑deficient tumors, suggesting that the 
mRNA expression levels of TAZ‑AXL‑CTGF may regulate 
certain MMR-associated signaling pathways. Since the 
majority of patients (441 of 519, 85%) in the dataset analyzed 
in the present study were MMR-proficient, the results 
obtained suggest that these patients should be further strati-
fied into favorable or unfavorable prognosis groups in order 
to improve their personalized treatment plan.
In conclusion, the results of this study indicate 
that the overexpression of the three‑gene signature, 
TAZ‑AXL‑CTGF, is associated with more aggressive clini-
copathological parameters of colon cancer, suggesting that 
these three genes may be important in colon cancer progres-
sion. However, since the present study was retrospective 
the results are limited, and thus, future in vitro analysis is 
required to understand the mechanism of TAZ-AXL-CTGF 
induced colon cancer progression. Subequently, these future 
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studies may result in the identification of potential drug 
targets for colon cancer.
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